Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
SEC-verified vehicles of the same sponsor, predating these roles and carrying none of them. The badge counts them; the figure beside this one does not.
Mergers closed across all 4 — these vehicles and the franchise's earlier ones together.
Announced but not closed, and still hunting — again over all 4.
No closed vehicle here has both a stored price and a filed trust value to score it against.
2 vehicles on file, newest listing first
none appears on more than one · 1 vehicle carry no counterparty filing we have read
Bihua Chen is the Founder, Chief Executive Officer, and Portfolio Manager of Cormorant Asset Management, LP, a Boston-based investment firm focused on innovative biotechnology, medical technology, and life science companies. She established Cormorant in February 2013 and has grown it to approximately $2.5 to $3 billion in assets under management. Under her leadership, Cormorant has invested in over 100 privately held, life science-focused companies, with more than 50 having completed initial public offerings. Prior to founding Cormorant, Ms. Chen managed a separately managed account focused on the healthcare sector as a sub-adviser to a large, multi-strategy hedge fund based in New York. She serves as the managing member of Cormorant Private Healthcare GP III, LLC and is based at Cormorant's offices at 200 Clarendon Street, 52nd Floor, Boston, Massachusetts.
Ms. Chen is currently the Chairperson and Chief Executive Officer of Helix Acquisition Corp. III (NASDAQ: HLXC), the third SPAC sponsored by an affiliate of Cormorant Asset Management. Helix III priced its upsized IPO of 17,250,000 Class A ordinary shares at $10.00 per share on January 23, 2026, raising $172.5 million, with Leerink Partners and Oppenheimer & Co. serving as joint bookrunners. The SPAC targets healthcare-related industries, particularly biotech, medtech, and life science sectors. She previously served as Chairperson and CEO of Helix Acquisition Corp. (Helix I), which raised $115 million in its October 2020 IPO and completed its merger with MoonLake Immunotherapeutics AG (Nasdaq: MLTX) in April 2022, delivering a return of approximately 56% from the $10 offer price. She also led Helix Acquisition Corp. II (HLXB), which raised $160 million in its February 2024 IPO and completed its merger with BridgeBio Oncology Therapeutics (BBOT) in August 2025, trading approximately 13% above the $10 offer price. John Schmid, a recurring board member across all three Helix SPACs, has noted his enthusiasm for working with Chen and her team on their latest vehicle.
Beyond her SPAC leadership, Ms. Chen holds or has held board seats and significant ownership positions at numerous public and private life science companies. She was appointed to the board of directors of Erasca, Inc. in March 2021, where she owns approximately 10.8 million shares. She has also served as a director and 10% owner of Akouos Inc and Avidity Biosciences Inc, and holds a 10% ownership stake in MoonLake Immunotherapeutics with approximately 25.4 million shares valued at over $436 million. She is also a director and 10% owner of BlossomHill Therapeutics Inc. Her estimated net worth is at least $728 million as of 2026. Cormorant's notable investment successes under her management include Prometheus Biosciences, Turning Point Therapeutics, and MyoKardia, each of which was acquired for more than $4 billion, as well as BridgeBio Pharma and Apellis Pharmaceuticals, both public companies with market capitalizations exceeding $1 billion.
Ms. Chen's educational background combines scientific and business training. She holds an MBA from the Wharton School, an M.S. in molecular biology from the Graduate School of Medical Sciences at Cornell Medical College, and a B.S. in genetics and genetic engineering from Fudan University in Shanghai, China. Her deep scientific expertise informs her investment approach, which emphasizes evaluating science, risk, and opportunity across both public and private biotech markets, separating signal from hype, and underwriting uncertainty in drug development to identify breakthroughs most likely to shape the future of medicine. She has shared these insights in industry forums, including a podcast appearance with MAI Capital Management's Evoke Advisors Division in July 2026.
This record is keyed to SEC CIK 0001599214 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 28 institutional-holder rows on these vehicles, under 24 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.